Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

被引:0
|
作者
Liu, Tong [1 ]
Meng, Guorui [1 ]
Ma, Shihui [1 ]
You, Junqi [1 ]
Yu, Liang [1 ]
He, Risheng [1 ]
Zhao, Xudong [1 ]
Cui, Yunfu [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; tumor immune microenvironment; review; OPEN-LABEL; INFUSION CHEMOTHERAPY; PLUS; MULTICENTER; BEVACIZUMAB; SINTILIMAB; LENVATINIB; EFFICACY; THERAPY; SAFETY;
D O I
10.3389/fimmu.2024.1455716
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among primary liver cancers, hepatocellular carcinoma is the most common pathological type. Its onset is insidious, and most patients have no obvious discomfort in the early stage, so it is found late, and the opportunity for surgical radical treatment is lost, resulting in a poor prognosis. With the introduction of molecular-targeted drugs represented by sorafenib, patients with middle- and late-stage liver cancer have regained the light of day. However, their therapeutic efficacy is relatively low due to the limited target of drug action, toxic side effects, and other reasons. At this time, the emergence of immunotherapy represented by immune checkpoint inhibitors (ICIs) well breaks this embarrassing situation, which mainly achieves the anti-tumor purpose by improving the tumor immune microenvironment. Currently, ICI monotherapy, as well as combination therapy, has been widely used in the clinic, further prolonging the survival of patients with advanced hepatocellular carcinoma. This article reviews the development of monotherapy and combination therapy for ICIs in advanced hepatocellular carcinoma and the latest research progress.
引用
下载
收藏
页数:13
相关论文
共 50 条
  • [1] Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
    Yin, Xiaoqiang
    Wu, Tongchui
    Lan, Yadong
    Yang, Wulin
    BIOSCIENCE REPORTS, 2022, 42 (02)
  • [2] Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
    Akbulut, Zeynep
    Aru, Basak
    Aydin, Furkan
    Demirel, Gulderen Yanikkaya
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [3] Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
    Chen, Yue
    Hu, Haoyue
    Yuan, Xianglei
    Fan, Xue
    Zhang, Chengda
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
    Zeng, Zhu
    Yang, Biao
    Liao, Zheng-Yin
    ONCOLOGY LETTERS, 2020, 20 (04)
  • [5] Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma
    Chan, Landon L.
    Chan, Stephen L.
    EXPERT OPINION ON EMERGING DRUGS, 2021, 26 (01) : 39 - 51
  • [6] Editorial on immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
    Ruff, Samantha M.
    Pawlik, Timothy M.
    IMMUNOTHERAPY, 2023, 15 (16) : 1323 - 1326
  • [7] Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma
    Nishida, Naoshi
    Kudo, Masatoshi
    CANCERS, 2020, 12 (05)
  • [8] Immune checkpoint inhibitors for hepatocellular carcinoma
    El Dika, Imane
    Khalil, Danny N.
    Abou-Alfa, Ghassan K.
    CANCER, 2019, 125 (19) : 3312 - 3319
  • [9] Immune checkpoint inhibitors for hepatocellular carcinoma
    Jensen, Christopher E.
    Loaiza-Bonilla, Arturo
    Bonilla-Reyes, Paula A.
    HEPATIC ONCOLOGY, 2016, 3 (03) : 201 - 211
  • [10] Lenvatinib With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma
    Teng, Yu-xian
    Guo, Ping-Ping
    Qin, Ke-Zhang
    Chen, Kang
    Papatheodoridis, George
    Xiang, Bang-De
    Mia, Liang
    Zhong, Jian-Hong
    EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2022, 6 (01): : 25 - 29